focus -WSS

focus

author：comprehensive 2025-09-03 11:52:55 - browse：21

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Tuberculosis patients need more than just free medication

WSS

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Feed a cold, starve a fever? Here’s what science says

The debate over Covid

Google's generative AI to analyze medical images — and talk to docs

'Brian's Song' at 50 still offers lessons about cancer for today

knowledge

focus

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

After half a century, Israel moves to evict squatter from his cave home on the beach

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After half a century, Israel moves to evict squatter from his cave home on the beach

Alkermes shareholders re

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kansas bar where gunfire wounded 9 last month closes permanently

Sports medicine is finally prioritizing gender equality

Judge in Trump's classified documents case questions use of out

focus

Feed a cold, starve a fever? Here’s what science says

Watch the official trailer for 'Ahsoka' series

Grail's uphill battle for Medicare to cover its cancer screening test

Vermont grapples with historic flooding as more rainstorms head for Northeast

Digital health funding stays low as a new reality sets in

With heat waves through August, officials warn of health risks

knowledge

focus

hotspot

hotspot